162 related articles for article (PubMed ID: 34417198)
1. FDA Approval Summary: Tivozanib for Relapsed or Refractory Renal Cell Carcinoma.
Chang E; Weinstock C; Zhang L; Fiero MH; Zhao M; Zahalka E; Ricks TK; Fourie Zirkelbach J; Qiu J; Yu J; Chen XH; Bhatnagar V; Goldberg KB; Tang S; Kluetz PG; Pazdur R; Ibrahim A; Beaver JA; Amiri-Kordestani L
Clin Cancer Res; 2022 Feb; 28(3):441-445. PubMed ID: 34417198
[TBL] [Abstract][Full Text] [Related]
2. Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial.
Beckermann KE; Asnis-Alibozek AG; Atkins MB; Escudier B; Hutson TE; Kasturi V; McDermott DF; Pal SK; Porta C; Rini BI; Verzoni E
Oncologist; 2024 Mar; 29(3):254-262. PubMed ID: 38262444
[TBL] [Abstract][Full Text] [Related]
3. Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.
Rini BI; Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; McDermott DF
Lancet Oncol; 2020 Jan; 21(1):95-104. PubMed ID: 31810797
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of tivozanib treatment after sorafenib in patients with advanced renal cell carcinoma: crossover of a phase 3 study.
Molina AM; Hutson TE; Nosov D; Tomczak P; Lipatov O; Sternberg CN; Motzer R; Eisen T
Eur J Cancer; 2018 May; 94():87-94. PubMed ID: 29547835
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity and safety of tivozanib (AV-951) in a phase II randomized discontinuation trial in patients with renal cell carcinoma.
Nosov DA; Esteves B; Lipatov ON; Lyulko AA; Anischenko AA; Chacko RT; Doval DC; Strahs A; Slichenmyer WJ; Bhargava P
J Clin Oncol; 2012 May; 30(14):1678-85. PubMed ID: 22493422
[TBL] [Abstract][Full Text] [Related]
6. Tivozanib for the treatment of renal cell carcinoma: results and implications of the TIVO-1 trial.
Mehta A; Sonpavde G; Escudier B
Future Oncol; 2014 Aug; 10(11):1819-26. PubMed ID: 25325825
[TBL] [Abstract][Full Text] [Related]
7. Tivozanib versus sorafenib as initial targeted therapy for patients with metastatic renal cell carcinoma: results from a phase III trial.
Motzer RJ; Nosov D; Eisen T; Bondarenko I; Lesovoy V; Lipatov O; Tomczak P; Lyulko O; Alyasova A; Harza M; Kogan M; Alekseev BY; Sternberg CN; Szczylik C; Cella D; Ivanescu C; Krivoshik A; Strahs A; Esteves B; Berkenblit A; Hutson TE
J Clin Oncol; 2013 Oct; 31(30):3791-9. PubMed ID: 24019545
[TBL] [Abstract][Full Text] [Related]
8. Final Overall Survival Results from a Phase 3 Study to Compare Tivozanib to Sorafenib as Third- or Fourth-line Therapy in Subjects with Metastatic Renal Cell Carcinoma.
Pal SK; Escudier BJ; Atkins MB; Hutson TE; Porta C; Verzoni E; Needle MN; Powers D; McDermott DF; Rini BI
Eur Urol; 2020 Dec; 78(6):783-785. PubMed ID: 32938569
[TBL] [Abstract][Full Text] [Related]
9. Final Data Analysis Supports Tivozanib as Superior Treatment for Patients With RCC.
Wright KM
Oncology (Williston Park); 2020 Jul; 34(7):257. PubMed ID: 32674211
[TBL] [Abstract][Full Text] [Related]
10. The role of tivozanib in advanced renal cell carcinoma therapy.
Escudier B; Porta C; Eisen T; Belsey J; Gibson D; Morgan J; Motzer R
Expert Rev Anticancer Ther; 2018 Nov; 18(11):1113-1124. PubMed ID: 30084668
[TBL] [Abstract][Full Text] [Related]
11. Tivozanib in relapsed or refractory advanced renal cell carcinoma: a focus on US approval.
Viray H; McDermott DF; Einstein DJ
Expert Rev Anticancer Ther; 2022 Jul; 22(7):695-702. PubMed ID: 35698870
[TBL] [Abstract][Full Text] [Related]
12. Tivozanib in Patients with Advanced Renal Cell Carcinoma Previously Treated With Axitinib: Subgroup Analysis from TIVO-3.
Meza L; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Pal SK; Rini B
Oncologist; 2023 Mar; 28(3):e167-e170. PubMed ID: 36576430
[TBL] [Abstract][Full Text] [Related]
13. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial.
Haas NB; Manola J; Uzzo RG; Flaherty KT; Wood CG; Kane C; Jewett M; Dutcher JP; Atkins MB; Pins M; Wilding G; Cella D; Wagner L; Matin S; Kuzel TM; Sexton WJ; Wong YN; Choueiri TK; Pili R; Puzanov I; Kohli M; Stadler W; Carducci M; Coomes R; DiPaola RS
Lancet; 2016 May; 387(10032):2008-16. PubMed ID: 26969090
[TBL] [Abstract][Full Text] [Related]
15. Safety and Efficacy of Tivozanib in First-Line mRCC: A Multicenter Compassionate-Use Study (Meet-Uro 16).
Basso U; Procopio G; Fornarini G; Massari F; Bearz A; Fratino L; Milella M; Bassanelli M; Ermacora P; Bimbatti D; Verzoni E; Rizzo M; Porta C
Oncology; 2021; 99(12):747-755. PubMed ID: 34583356
[TBL] [Abstract][Full Text] [Related]
16. Q-TWiST Analysis of Tivozanib Versus Sorafenib in Patients With Advanced Renal Cell Carcinoma in the TIVO-3 Study.
Szarek M; Needle MN; Rini BI; Pal SK; McDermott DF; Atkins MB; Hutson TE; Escudier BJ
Clin Genitourin Cancer; 2021 Oct; 19(5):468.e1-468.e5. PubMed ID: 33980467
[TBL] [Abstract][Full Text] [Related]
17. Tivozanib, a highly potent and selective inhibitor of VEGF receptor tyrosine kinases, for the treatment of metastatic renal cell carcinoma.
Jacob A; Shook J; Hutson TE
Future Oncol; 2020 Oct; 16(28):2147-2164. PubMed ID: 32692256
[TBL] [Abstract][Full Text] [Related]
18. Temporal Characteristics of Adverse Events of Tivozanib and Sorafenib in Previously Treated Kidney Cancer.
Zengin ZB; Pal SK; McDermott DF; Escudier B; Hutson TE; Porta C; Verzoni E; Atkins MB; Kasturi V; Rini B
Clin Genitourin Cancer; 2022 Dec; 20(6):553-557. PubMed ID: 36096984
[TBL] [Abstract][Full Text] [Related]
19. Tivozanib for the treatment of metastatic renal cancer.
Wong HH; Eisen T
Expert Rev Anticancer Ther; 2013 Jun; 13(6):649-60. PubMed ID: 23773100
[TBL] [Abstract][Full Text] [Related]
20. Profile of tivozanib and its potential for the treatment of advanced renal cell carcinoma.
Cowey CL
Drug Des Devel Ther; 2013; 7():519-27. PubMed ID: 23818763
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
